Network

International

Horizon 2020

  • CARE: Common Action against HIV/TB/HCV across the regions of Europe, 2019-2024
  • CORVOS: Marie Sklodowska-Curie Joint European PhD: Complement regulation and variations in opportunistic infections, 2020-2023
  • DRTB-HDT: Stratified host-directed therapy for drug-resistant tuberculosis: a randomized controlled multi-centre trial, 2020-2023
  • ERA4TB: European Regime Accelerator for Tuberculosis, 2020-2025
  • MepAnti: Marie Skodowska-Curie Innovative Training Networks: Exploiting the methylerythritol phosphate pathway as a source of drug targets for novel anti-infectives, 2020-2024
  • Unite4TB: Accelerating the development of new treatment regimens for Tuberculosis, 2021-2028

 European and Developing Countries Clinical Trials Partnership (EDCTP)

  • VITALITY: Vitamin D for adolescents with HIV to reduce musculoskeletal morbidity and immunpathology: an individually randomised, double-blinded placebo-controlled trial, 2019-2024
  • Core-NB: Collision of three global pandemics: the effect of tuberculosis and HIV on the epidemiological, clinical, virological and immunological trajectory of COVID-19 in Botswana and Namibia, 2021-2023
  • ClicTB: The purpose of Clic-TB is to identify and validate a new combination TB drug consisting of one or more novel development candidates for transition to definitive late-stage trials. Borstel will further validate biomarkers as novel measures of early bactericidal activity, which will include PET-CT scans of affected patients in South Africa, 2019-2024
  • CUT TB: Community and Universal Testing for TB Contacts, 2020-2024
  • STooL4TB: Evaluating a new stool based qPCR for diagnosis of tuberculosis in children and people living with HIV, 2020-2024

National Institute of Health (NIH)

  • Quantifiable stool based TB PCR to improve diagnostics and treatment, 2019-2023
  • Improved understanding of TB transmission by accounting for within-host heterogeneity of M. tuberculosis – a population-based molecular epidemiology study in a high HIV prevalent setting, 2020-2025

Further Cooperations:

  • University of Xiamen: Xiamen-Borstel Joint Laboratory of Autoimmunity, Medical College of Xiamen University. Contact: This email address is being protected from spambots. You need JavaScript enabled to view it.
  • University of Namibia: Tuberculosis research laboratories and a training curriculum on infectious diseases. Co-financed by the Schleswig-Holstein TB Society. Contact: This email address is being protected from spambots. You need JavaScript enabled to view it.; This email address is being protected from spambots. You need JavaScript enabled to view it.